Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function

Journal of Virology

Volumn 88, Issue 15, 2014, Pages 8479-8489

  Hou, Wanqiu ^a,b   Jin, Young Hee ^a,c   Kang, Hyun Seok ^a   Kim, Byung S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CELL LINE; CENTRAL NERVOUS SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEMYELINATING DISEASE; FEMALE; GENE ACTIVATION; LYMPHOCYTE FUNCTION; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NEOPLASM; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION; TH17 CELL; UPREGULATION; VIRUS INFECTION;

ANIMALS; APOPTOSIS; FEMALE; IMMUNE EVASION; INTERLEUKIN-17; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; THEILOVIRUS;

EID: 84903886499     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00724-14     Document Type: Article

References (54)

1. Pevear DC, Calenoff M, Rozhon E, Lipton HL. 1987. Analysis of the complete nucleotide sequence of the picornavirus Theiler's murine encephalomyelitis virus indicates that it is closely related to cardioviruses. J. Virol. 61:1507-1516.
2. Lipton HL, Dal Canto MC. 1976. Chronic neurologic disease in Theiler's virus infection of SJL/J. mice. J. Neurol. Sci. 30:201-207. http://dx.doi.org/10.1016/0022-510X(76)90267-7.
3. Dal Canto MC, Lipton HL. 1977. Multiple sclerosis. Animal model: Theiler's virus infection in mice. Am. J. Pathol. 88:497-500.
4. Dal Canto MC, Kim BS, Miller SD, Melvold RW. 1996. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelination: a model for human multiple sclerosis. Methods 10:453-461. http://dx.doi.org/10.1006/meth.1996.0123.
5. Hou W, Kang HS, Kim BS. 2009. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J. Exp. Med. 206:313-328. http://dx.doi.org/10.1084/jem.20082030.
6. So EY, Kang MH, Kim BS. 2006. Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3. Glia 53:858-867. http://dx.doi.org/10.1002/glia.20346.
7. So EY, Kim BS. 2009. Theiler's virus infection induces TLR3-dependent upregulation of TLR2 critical for proinflammatory cytokine production. Glia 57:1216-1226. http://dx.doi.org/10.1002/glia.20843.
8. Jin YH, Kaneyama T, Kang MH, Kang HS, Koh CS, Kim BS. 2011. TLR3 signaling is either protective or pathogenic for the development of Theiler's virus-induced demyelinating disease depending on the time of viral infection. J. Neuroinflammation 8:178. http://dx.doi.org/10.1186/1742-2094-8-178.
9. Kim BS, Jin YH, Meng L, Hou W, Kang HS, Park HS, Koh CS. 2012. IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease. J. Neuroinflammation 9:217. http://dx.doi.org/10.1186/1742-2094-9-217.
10. Pullen LC, Park SH, Miller SD, Dal Canto MC, Kim BS. 1995. Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus-induced demyelinating disease. J. Immunol. 155:4497-4503.
11. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, Katz-Levy Y, Carrizosa A, Kim BS. 1997. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3:1133-1136. http://dx.doi.org/10.1038/nm1097-1133.
12. Schattner A, Rager-Zisman B. 1990. Virus-induced autoimmunity. Rev. Infect. Dis. 12:204-222. http://dx.doi.org/10.1093/clinids/12.2.204.
13. Horwitz MS, Sarvetnick N. 1999. Viruses, host responses, and autoimmunity. Immunol. Rev. 169:241-253. http://dx.doi.org/10.1111/j.1600-065X.1999.tb01319.x.
14. Arzumanyan A, Reis HM, Feitelson MA. 2013. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 13:123-135. http://dx.doi.org/10.1038/nrc3449.
15. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. 1999. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 274:23013-23019. http://dx.doi.org/10.1074/jbc.274.33.23013.
16. Hideshima T, Nakamura N, Chauhan D, Anderson KC. 2001. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20:5991-6000. http://dx.doi.org/10.1038/sj.onc.1204833.
17. Graeve L, Baumann M, Heinrich PC. 1993. Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense. Clin. Investig. 71:664-671.
18. Ishihara K, Hirano T. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13:357-368. http://dx.doi.org/10.1016/S1359-6101(02)00027-8.
19. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238. http://dx.doi.org/10.1038/nature04753.
20. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967-974. http://dx.doi.org/10.1038/ni1488.
21. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ. 2007. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8:1390-1397. http://dx.doi.org/10.1038/ni1539.
22. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183:2593-2603. http://dx.doi.org/10.1084/jem.183.6.2593.
23. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608. http://dx.doi.org/10.1016/0092-8674(93)90508-N.
24. Kishimoto T. 2005. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23:1-21. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115806.
25. Gaffen SL. 2009. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9:556-567. http://dx.doi.org/10.1038/nri2586.
26. Lee SY, Kwok SK, Son HJ, Ryu JG, Kim EK, Oh HJ, Cho ML, Ju JH, Park SH, Kim HY. 2013. IL-17-mediated Bcl-2 expression regulates survival of fibroblast like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthr. Res. Ther. 15:R31. http://dx.doi.org/10.1186/ar4179.
27. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, Kim HY. 2004. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB-and PI3-kinase/Akt-dependent pathways. Arthr. Res. Ther. 6:R120-R128. http://dx.doi.org/10.1186/ar1038.
28. Hanai Y, Tokuda H, Ohta T, Matsushima-Nishiwaki R, Takai S, Kozawa O. 2006. Phosphatidylinositol 3-kinase/Akt auto-regulates PDGFBB-stimulated interleukin-6 synthesis in osteoblasts. J. Cell. Biochem. 99: 1564-1571. http://dx.doi.org/10.1002/jcb.21007.
29. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206:1457-1464. http://dx.doi.org/10.1084/jem.20090207.
30. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. 1992. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 89:232-235. http://dx.doi.org/10.1073/pnas.89.1.232.
31. Hou W, So EY, Kim BS. 2007. Role of dendritic cells in differential susceptibility to viral demyelinating disease. PLoS Pathog. 3:e124. http://dx.doi.org/10.1371/journal.ppat.0030124.
32. Subramaniam SV, Cooper RS, Adunyah SE. 1999. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem. Biophys. Res. Commun. 262:14-19. http://dx.doi.org/10.1006/bbrc.1999.1156.
33. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J. 2007. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U.S.A. 104:7391-7396. http://dx.doi.org/10.1073/pnas.0609757104.
34. Schwandner R, Yamaguchi K, Cao Z. 2000. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J. Exp. Med. 191:1233-1240. http://dx.doi.org/10.1084/jem.191.7.1233.
35. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783-801. http://dx.doi.org/10.1016/j.cell.2006.02.015.
36. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. 1994. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J. Immunol. 153:3811-3821.
37. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. 1997. Cytokines and immunity to viral infections. Immunol. Rev. 159:119-135. http://dx.doi.org/10.1111/j.1600-065X.1997.tb01011.x.
38. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. 2003. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22:7809-7818. http://dx.doi.org/10.1038/sj.onc.1207084.
39. Kang MH, So EY, Park H, Kim BS. 2008. Replication of Theiler's virus requires NF-kappaB-activation: higher viral replication and spreading in astrocytes from susceptible mice. Glia 56:942-953. http://dx.doi.org/10.1002/glia.20668.
40. Jin YH, Kim SJ, So EY, Meng L, Colonna M, Kim BS. 2012. Melanoma differentiation-associated gene 5 is critical for protection against Theiler's virus-induced demyelinating disease. J. Virol. 86:1531-1543. http://dx.doi.org/10.1128/JVI.06457-11.
41. Zhong Z, Wen Z, Darnell JE, Jr. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95-98. http://dx.doi.org/10.1126/science.8140422.
42. Bhattacharya S, Ray RM, Johnson LR. 2005. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem. J. 392:335-344. http://dx.doi.org/10.1042/BJ20050465.
43. Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, Xiao J, Lu Y, Giltiay N, Liu J, Kordula T, Zhang QW, Vallance B, Swaidani S, Aronica M, Tuohy VK, Hamilton T, Li X. 2007. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8:247-256. http://dx.doi.org/10.1038/ni1439.
44. Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV. 2003. IL-6 induces NF-kappa B activation in the intestinal epithelia. J. Immunol. 171:3194-3201. http://dx.doi.org/10.4049/jimmunol.171.6.3194.
45. Barre B, Avril S, Coqueret O. 2003. Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J. Biol. Chem. 278:2990-2996. http://dx.doi.org/10.1074/jbc.M210422200.
46. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. 1997. Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 91:231-241. http://dx.doi.org/10.1016/S0092-8674(00)80405-5.
47. Strasberg Rieber M, Welch DR, Rieber M. 2001. Suppression of C8161 melanoma metastatic ability by chromosome 6 induces differentiationassociated tyrosinase and decreases proliferation on adhesion-restrictive substrates mediated by overexpression of p21WAF1 and down-regulation of bcl-2 and cyclin D3. Biochem. Biophys. Res. Commun. 281:159-165. http://dx.doi.org/10.1006/bbrc.2001.4330.
48. Wu Q, Kirschmeier P, Hockenberry T, Yang TY, Brassard DL, Wang L, McClanahan T, Black S, Rizzi G, Musco ML, Mirza A, Liu S. 2002. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J. Biol. Chem. 277:36329-36337. http://dx.doi.org/10.1074/jbc.M204962200.
49. Sheikh MS, Garcia M, Zhan Q, Liu Y, Fornace AJ, Jr. 1996. Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ. 7:1599-1607.
50. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. 1999. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11:709-719. http://dx.doi.org/10.1016/S1074-7613(00)80145-4.
51. Sepulveda P, Encabo A, Carbonell-Uberos F, Minana MD. 2007. BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. Cell Death Differ. 14:378-380. http://dx.doi.org/10.1038/sj.cdd.4402007.
52. Dooher JE, Paz-Priel I, Houng S, Baldwin AS, Jr, Friedman AD. 2011. C/EBPalpha, C/EBPalpha oncoproteins, or C/EBPbeta preferentially bind NF-kappaB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction. Mol. Cancer Res. 9:1395-1405. http://dx.doi.org/10.1158/1541-7786.MCR-11-0072.
53. Zou W, Restifo NP. 2010. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10:248-256. http://dx.doi.org/10.1038/nri2742.
54. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38:904-910. http://dx.doi.org/10.1016/j.ctrv.2012.04.007.